Long-term disease-free survival after MIBG therapy for metastatic pheochromocytoma.
BMJ Case Rep
; 17(7)2024 Jul 05.
Article
en En
| MEDLINE
| ID: mdl-38969389
ABSTRACT
Pheochromocytomas are rare tumours originating in chromafï¬n cells, representing 0.1%-1% of all secondary hypertension cases. The majority are benign and unilateral, characterised by the production of catecholamines and other neuropeptides. Mainly located in the adrenal gland, they are more frequent between the third and fifth decades of life. Iodine-131 metaiodobenzylguanidine (131I-MIBG), a radiopharmaceutical agent used for scintigraphic localisation of pheochromocytomas, has been employed to treat malignant pheochromocytomas since 1983 in a few specialised centres around the world. We reviewed our clinical experience in one such case of a young lady who presented with history of abdominal pain, headache and lower back pain. On evaluation, ultrasonography revealed a right adrenal mass and elevated urine vanillylmandelic acid levels. Following surgical resection and histopathological confirmation of pheochromocytoma, MIBG scintigraphy revealed osseous metastases and hence, she underwent 131I-MIBG therapy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Feocromocitoma
/
Neoplasias de las Glándulas Suprarrenales
/
Radiofármacos
/
3-Yodobencilguanidina
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
BMJ Case Rep
Año:
2024
Tipo del documento:
Article
País de afiliación:
India